Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Health Discovery Corporation
Health Discovery Corporation Announces Successful Phase II Clinical Trial Results for New Gene-Based Molecular Diagnostic Test for Prostate Cancer
July 19th, 2008
Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced the successful phase II clinical trial results for HDC's new gene-based molecular diagnostic test for prostate cancer licensed exclusively to Clarient (Nasdaq: CLRT), in which HDC will receive a 30 percent royalty on each test performed based on the per test reimbursement received by Clarient. In addition to the commercialization license HDC granted to Clarient, HDC retained the right to also commercialize this molecular diagnostic test for prostate cancer in one or more clinical laboratories that HDC elects to own and/or operate. Results from both the Phase I and Phase II clinical validation studies now...
Source: Law & Health Weekly (2008-07-19)
|
